Literature DB >> 26000813

Effects of simvastatin on the expression of inducible nitric oxide synthase and brain-derived neurotrophic factor in a lipopolysaccharide-induced rat model of Parkinson disease.

Wang Tan1,2, Cao Xue-bin3, Zhang Tian2, Chen Xiao-wu2, Huang Pei-pei3, Chen Zhi-bin2, Tang Bei-sha1.   

Abstract

OBJECTIVE: To investigate the effects of simvastatin on the expression of inducible nitric oxide synthase (iNOS) and brain-derived neurotrophic factor (BDNF) in the substantia nigra in a lipopolysaccharide (LPS)-induced rat model of Parkinson disease (PD), and to study the mechanisms underlying the neuroprotective effects of simvastatin in PD.
METHODS: The LPS-PD model was established by injection of LPS (5 mg/mL, 2.0 μL) into the right substantia nigra compacta (SNC). Rats in the sham-operated group received saline. The simvastatin treatment group was intraperitoneally administered simvastatin (5 mg/kg, 2.0 μL) at 1 h before, and daily for 14 days after surgery, while the sham-operated and LPS-model groups received saline. Iba-1-positive cells and tyrosine hydroxylase (TH), as well as iNOS and BDNF in the SNC were detected by immunohistochemistry and Western blotting, respectively. The effect of simvastatin in the PD model was also examined in behavioral tests.
RESULTS: The LPS-model group exhibited typical animal PD behaviors. Compared with the control group, the LPS-model group exhibited a decreased number of DA neurons (p < 0.01) in the SNC, as well as increases in the Iba-1-positive cell number and iNOS expression (p < 0.05), while BDNF expression was downregulated (p < 0.01). These effects were inhibited by simvastatin treatment (p < 0.05).
CONCLUSION: Simvastatin mediates a protective effect on dopaminergic neurons in the SNC in the LPS-PD model, possibly by promoting neuronal repair and regeneration, and by inhibiting oxidative stress, thus improving substantia nigra function.

Entities:  

Keywords:  BDNF; Parkinson disease; Simvastatin; iNOS

Mesh:

Substances:

Year:  2015        PMID: 26000813     DOI: 10.3109/00207454.2015.1012758

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  6 in total

1.  Association between Statin Use and Risk of Parkinson's Disease: Evidence from 18 Observational Studies Comprising 3.7 Million Individuals.

Authors:  Chieh-Chen Wu; Md Mohaimenul Islam; An-Jen Lee; Chun-Hsien Su; Yung-Ching Weng; Chih-Yang Yeh; Hsun-Hua Lee; Ming-Chin Lin
Journal:  J Pers Med       Date:  2022-05-19

2.  Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease in mice.

Authors:  Xiaojin Shi; Yu-Hua Chen; Hao Liu; Hong-Dang Qu
Journal:  Mol Med Rep       Date:  2016-07-28       Impact factor: 2.952

3.  Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.

Authors:  Camille B Carroll; Richard K H Wyse
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

4.  Effects of simvastatin on iNOS and caspase‑3 levels and oxidative stress following smoke inhalation injury.

Authors:  Rong-Qiang Yang; Peng-Fei Guo; Zhao Ma; Cheng Chang; Qing-Nan Meng; Ya Gao; Imran Khan; Xiao-Bo Wang; Zheng-Jun Cui
Journal:  Mol Med Rep       Date:  2020-08-04       Impact factor: 2.952

5.  Effect of statins on Parkinson's disease: A systematic review and meta-analysis.

Authors:  Junqiang Yan; Liang Qiao; Jing Tian; Anran Liu; Jiannan Wu; Jiarui Huang; Mengmeng Shen; Xiaoyi Lai
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

6.  Kir6.1/K-ATP channel modulates microglia phenotypes: implication in Parkinson's disease.

Authors:  Ren-Hong Du; Hong-Bin Sun; Zhao-Li Hu; Ming Lu; Jian-Hua Ding; Gang Hu
Journal:  Cell Death Dis       Date:  2018-03-14       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.